Literature DB >> 21763167

Rate of progression and predictive factors for pulmonary outcome in children and adults with Pompe disease.

N A M E van der Beek1, C I van Capelle, K I van der Velden-van Etten, W C J Hop, B van den Berg, A J J Reuser, P A van Doorn, A T van der Ploeg, H Stam.   

Abstract

Respiratory insufficiency is a serious threat to patients with Pompe disease, a neuromuscular disorder caused by lysosomal acid alpha-glucosidase deficiency. Innovative therapeutic options which may stabilize pulmonary function have recently become available. We therefore determined proportion and severity of pulmonary involvement in patients with Pompe disease, the rate of progression of pulmonary dysfunction, and predictive factors for poor respiratory outcome. In a single-center, prospective, cohort study, we measured vital capacity (VC) in sitting and supine positions, as well as maximum inspiratory (MIP) and expiratory (MEP) mouth pressures, and end expiratory CO(2) in 17 children and 75 adults with Pompe disease (mean age 42.7 years, range 5-76 years). Seventy-four percent of all patients, including 53% of the children, had some degree of respiratory dysfunction. Thirty-eight percent had obvious diaphragmatic weakness. Males appeared to have more severe pulmonary involvement than females: at a group level, their mean VC was significantly lower than that of females (p<0.001), they used mechanical ventilation more often than females (p=0.042) and the decline over the course of the disease was significantly different between males and females (p=0.003). Apart from male gender, severe skeletal muscle weakness and long disease duration were the most important predictors of poor respiratory status. During follow-up (average 1.6 years, range 0.5-4.2 years), three patients became ventilator dependent. Annually, there were average decreases in VC in upright position of 0.9% points (p=0.09), VC in supine position of 1.2% points (p=0.049), MIP of 3.2% points (p=0.018) and MEP of 3.8% points (p<0.01). We conclude that pulmonary dysfunction in Pompe disease is much more common than generally thought. Males, patients with severe muscle weakness, and those with advanced disease duration seem most at risk.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21763167     DOI: 10.1016/j.ymgme.2011.06.012

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  36 in total

1.  36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy.

Authors:  Caroline Regnery; Cornelia Kornblum; Frank Hanisch; Stefan Vielhaber; Nicola Strigl-Pill; Birgit Grunert; Wolfgang Müller-Felber; Franz Xaver Glocker; Matthias Spranger; Marcus Deschauer; Eugen Mengel; Benedikt Schoser
Journal:  J Inherit Metab Dis       Date:  2012-01-31       Impact factor: 4.982

2.  Safety and efficacy of short- and long-term inspiratory muscle training in late-onset Pompe disease (LOPD): a pilot study.

Authors:  Stephan Wenninger; Eva Greckl; Haris Babačić; Kristina Stahl; Benedikt Schoser
Journal:  J Neurol       Date:  2018-11-14       Impact factor: 4.849

3.  Comparison of EQ-5D and SF-6D utilities in Pompe disease.

Authors:  T A Kanters; W K Redekop; M E Kruijshaar; A T van der Ploeg; M P M H Rutten-van Mölken; L Hakkaart
Journal:  Qual Life Res       Date:  2014-10-24       Impact factor: 4.147

4.  Ten years of the international Pompe survey: patient reported outcomes as a reliable tool for studying treated and untreated children and adults with non-classic Pompe disease.

Authors:  J C van der Meijden; D Güngör; M E Kruijshaar; A D J Muir; H A Broekgaarden; A T van der Ploeg
Journal:  J Inherit Metab Dis       Date:  2014-08-12       Impact factor: 4.982

5.  Respiratory function in late-onset Pompe disease patients receiving long-term enzyme replacement therapy for more than 48 months.

Authors:  Ilka Schneider; Frank Hanisch; Tobias Müller; Bernd Schmidt; Stephan Zierz
Journal:  Wien Med Wochenschr       Date:  2012-11-19

6.  Correction of Biochemical Abnormalities and Improved Muscle Function in a Phase I/II Clinical Trial of Clenbuterol in Pompe Disease.

Authors:  Dwight D Koeberl; Laura E Case; Edward C Smith; Crista Walters; Sang-Oh Han; Yanzhen Li; Wei Chen; Christoph P Hornik; Kim M Huffman; William E Kraus; Beth L Thurberg; David L Corcoran; Deeksha Bali; Nenad Bursac; Priya S Kishnani
Journal:  Mol Ther       Date:  2018-07-05       Impact factor: 11.454

7.  A Newborn with Infantile-Onset Pompe Disease Improving after Administration of Enzyme Replacement Therapy: Case Report.

Authors:  Meltem Bor; Ozkan Ilhan; Evren Gumus; Solmaz Ozkan; Meryem Karaca
Journal:  J Pediatr Intensive Care       Date:  2020-07-15

8.  Sleep-Disordered Breathing and Effects of Noninvasive Ventilation in Patients with Late-Onset Pompe Disease.

Authors:  Matthias Boentert; Bianca Dräger; Christian Glatz; Peter Young
Journal:  J Clin Sleep Med       Date:  2016-12-15       Impact factor: 4.062

9.  Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study.

Authors:  Juna M de Vries; Nadine A M E van der Beek; Wim C J Hop; Francois P J Karstens; John H Wokke; Marianne de Visser; Baziel G M van Engelen; Jan B M Kuks; Anneke J van der Kooi; Nicolette C Notermans; Catharina G Faber; Jan J G M Verschuuren; Michelle E Kruijshaar; Arnold J J Reuser; Pieter A van Doorn; Ans T van der Ploeg
Journal:  Orphanet J Rare Dis       Date:  2012-09-26       Impact factor: 4.123

10.  Management of a pregnancy complicated by pompe disease.

Authors:  Jennifer Weida; B E Hainline; C Bodkin; M K Williams
Journal:  Case Rep Obstet Gynecol       Date:  2012-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.